Research location
Prien am Chiemsee
Germany
Advertisement
Research activity in Prien am Chiemsee
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 10 trials and 10 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Prien am Chiemsee
10 linked trials · page 1 of 1A Study for Tysabri Participant PreferenceNCT05304520 · 2021-10-12 · 1 site observation
COMPLETED
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)NCT01665144 · 2012-12-20 · 1 site observation
COMPLETED
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)NCT01585298 · 2012-04-29 · 1 site observation
COMPLETED
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple SclerosisNCT01490840 · 2011-11-01 · 1 site observation
TERMINATED
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01247324 · 2011-08-31 · 1 site observation
COMPLETED
Long-Term Safety and Efficacy Study of Peginterferon Beta-1aNCT01332019 · 2011-04-01 · 1 site observation
COMPLETED
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake InhibitorNCT01185340 · 2011-03-01 · 1 site observation
COMPLETED
Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisNCT01201356 · 2010-09-13 · 1 site observation
COMPLETED
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) PatientsNCT01127750 · 2010-05-01 · 1 site observation
COMPLETED
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple SclerosisNCT00906399 · 2009-06-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.